PROCEPT BioRobotics Corp (NAS:PRCT)

Q1 2026 Procept Biorobotics Corp Earnings Call Transcript

Apr 29, 2026 / 08:30 PM GMT

Release Date Price: $21.71 (-5.73%)

Transcript 10-Q8-K

Key Points

Positve

PROCEPT BioRobotics Corp (PRCT) reported a total revenue of $83.1 million for Q1 2026, representing a 20% year-over-year growth.
The company achieved a gross margin of 65% in Q1 2026, an improvement from 61% in Q4 2025, driven by increased pricing discipline and better cost structure leverage.
The average selling price for U.S. Hydro Systems reached an all-time high of approximately $485,000, a 14% increase compared to Q4 2025.
The AquaBeam replacement program received early positive customer response, indicating potential for a growing replacement cycle.
The European Association of Urology updated its guidelines to strongly recommend aquaablation therapy, enhancing its credibility and adoption potential in the market.

Negative

PROCEPT BioRobotics Corp (PRCT) reported a net loss of $31.6 million for Q1 2026, compared to a net loss of $24.7 million in Q1 2025.
Adjusted EBITDA was a loss of $18.1 million in Q1 2026, an increase from a loss of $15.8 million in the prior-year period.
The realignment of the commercial organization caused short-term disruptions, affecting Q1 procedure growth.
Handpiece sales were below the target of one-to-one with procedures, indicating potential inventory and sales alignment issues.
Operating expenses increased to $86.6 million in Q1 2026 from $71.6 million in the prior-year period, reflecting higher investment needs.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PRCT.OQ - Procept Biorobotics Corp
Q1 2026 Procept Biorobotics Corp Earnings Call
Apr 29, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon, and welcome to ProSat BioRobotics First Quarter 2026 Earnings Conference Call. At this time, all participants are in listen-only mode. We will be facilitating a question-and-answer session towards the end of today's call. As a reminder, this call is being recorded for replay purposes. I would now like to turn the call over to Matt Baxo, Vice President, Investor Relations, for a few introductory comments.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Good afternoon, and thank you for joining Procept BioRobotics' First Quarter 2026 Earnings Conference Call.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.